

SEATTLE GENETICS INC /WA  
Form 4  
October 11, 2016

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**SIEGALL CLAY B**

2. Issuer Name and Ticker or Trading Symbol  
**SEATTLE GENETICS INC /WA [SGEN]**

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)  
21823 30TH DRIVE SE  
(Street)

3. Date of Earliest Transaction (Month/Day/Year)  
10/06/2016

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
President and CEO

BOTHELL, WA 98021

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|
|                                 |                                      |  | Code                           | V   | Amount  | (A) or (D)   | Price   |
| Common Stock                    | 10/06/2016                           |  | M                              |   | 3,242   | A  | \$ 10.2   |
|                                 |                                      |  |                                |   |   |  | 642,077 <sup>(1)</sup>                                |
| Common Stock                    | 10/06/2016                           |  | S <sup>(2)</sup>               |   | 3,242   | D  | \$ 54.4087  |
|                                 |                                      |  |                                |   |   |  | 638,835 <sup>(1)</sup>                                |
|                                 |                                      |  |                                |   |   |  | <sup>(3)</sup>  |
| Common Stock                    | 10/06/2016                           |  | M                              |   | 11,223  | A  | \$ 10.29  |
|                                 |                                      |  |                                |   |   |  | 650,058 <sup>(1)</sup>                                |
| Common Stock                    | 10/06/2016                           |  | S <sup>(2)</sup>               |   | 11,223  | D  | \$ 54.4087  |
|                                 |                                      |  |                                |   |   |  | 638,835 <sup>(1)</sup>                                |
|                                 |                                      |  |                                |   |   |  | <sup>(3)</sup>  |

Edgar Filing: SEATTLE GENETICS INC /WA - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Security (Instr. 3 and 4) | 8. Amount or Number of Shares |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|-------------------------------|
| Non-Qualified Stock Option (right to buy)  | \$ 10.2  | 10/06/2016                           |  | M                              | 3,242   | <u>(4)</u> 05/25/2017                                    | Common Stock  | 3,242                         |
| Non-Qualified Stock Option (right to buy)  | \$ 10.29   | 10/06/2016                           |  | M                              | 11,223  | <u>(5)</u> 08/28/2017                                    | Common Stock  | 11,223                        |

## Reporting Owners

| Reporting Owner Name / Address                             | Relationships |           |                   |       |
|--|---------------|-----------|-------------------|-------|
|  | Director      | 10% Owner | Officer           | Other |
| SIEGALL CLAY B<br>21823 30TH DRIVE SE<br>BOTHELL, WA 98021 | X             |           | President and CEO |       |

## Signatures

/s/ Jean Liu 10/10/2016

\_\_Signature of  
Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
- (2) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- (3) Reflects sales of ordinary shares executed in multiple transactions at prices ranging from \$54.03 to \$54.69. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the

Edgar Filing: SEATTLE GENETICS INC /WA - Form 4

sales were effected.

- (4) Shares vested at a rate of 25% on 5/25/08 and monthly thereafter until all the shares were fully vested on 5/25/11.
- (5) Shares vested at a rate of 25% on 8/28/08 and monthly thereafter until all the shares were fully vested on 8/28/11.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.